Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 85

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 85
---
  
                        and climb to $2.28 billion by the end of 2034, expanding at a CAGR of 6.3% between 2024 and 2034.                    
---------------------------------------------------------------------------------------------------------------------------------------------

◾                           Methicillin-Resistant Staphylococcus Aureus (MRSA) – One of the most common Staphylococcus                        
      aureus infections is caused by MRSA, which is a multi-drug resistant bacterium, responsible for several difficult-to-treat infections   
    in humans, leading to tens of thousands of annual cases of mortality in the U.S. MRSA is the leading causative agent for hospital acquired
    infections and has recently been documented as community-acquired as well as livestock-acquired. Current medical treatments include broad 
      spectrum antibiotics that are becoming increasingly ineffective. Bloomberg estimates according to a report published on September 24,   
     2019, which is not incorporated by reference herein, that the current MRSA market was valued at approximately $2.15 billion in 2023 and  
                                           is projected to grow at a CAGR of 5.51% from 2024 to 203011.                                       
----------------------------------------------------------------------------------------------------------------------------------------------
Competition
 
The biotechnology and pharmaceutical industries are characterized by rapid growth and a dynamic landscape of proprietary therapeutic candidates. The development and commercialization of new drug and biologic products is highly competitive and is characterized by rapid and substantial technological development and product innovations. While we believe that our computational platform and microbial drug candidates, coupled with our resources and industry expertise, give us a competitive advantage in the field, we face competition from a variety of institutions, including larger pharmaceutical companies with more resources. Specialty biotechnology companies, academic research institutions, governmental agencies, as well as public and private institutions are also potential sources of competitive products and technologies.
 
In both inflammatory diseases and oncology, we anticipate intensifying competition as new therapies are approved and advanced technologies become available. Many of our competitors, either alone or with strategic partners, have considerably greater financial, technical, and human resources than we do.
 
Significant competition exists in the immuno-oncology and inflammatory diseases field, where we are developing our first drug candidates in oncology and IBD. Although our rationally-designed microbial consortium approach is unique relative to most other existing or investigational therapies in immuno-oncology, we will need to compete with all currently or imminently available therapies within the indications where our development is focused. Although there is a wide range of potentially competitive mechanisms,